Peninsula startup lands $30 million for vaccine targeting deadly infant infection
A South San Francisco company landed a $30 million investment to take an experimental vaccine into clinical trials against a deadly virus in infants and the elderly.
Meissa Vaccines Inc., launched five years ago by a former Emory University researcher Marty Moore and ex-MedImmune scientist Roderick Tang, landed the cash in a Series A financing by Morningside Ventures to develop a longer-lasting, universal vaccine against respiratory syncytial virus.
RSV is be st known for causing pneumonia and inflaming…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Clinical Trials | Health Management | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Respiratory Medicine | Vaccines